TSRO TESARO Inc.

113.60
-4.93  -4%
Previous Close 118.53
Open 117.80
Price To book 15.39
Market Cap 6154958646
Shares 54,180,974
Volume 1,005,641
Short Ratio 8.23
Av. Daily Volume 853,523

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data at ESMO September 9, 2017.
Niraparib - AVANOVA
Ovarian cancer
Phase 1/2 enrolling. Initial data presented at ASCO investor event. ORR 4/13 patients. Further data at ESMO September 11, 2017.
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Phase 3 trial to continue enrolling through 2017.
Niraparib - PRIMA
First-line ovarian cancer
CRL January 11 2017. Resubmission noted with new PDUFA October 25, 2017.
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 3 trial no longer be expected to serve as a registration trial - noted March 27, 2017.
Niraparib - BRAVO
Cancer - breast
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
Phase 2 data due 2H 2017.
Niraparib - (QUADRA trial)
Cancer - ovarian
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients

Latest News

  1. The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer
  2. TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : October 13, 2017
  3. See what the IHS Markit Score report has to say about TESARO Inc.
  4. Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?
  5. The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
  6. TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : October 2, 2017
  7. TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 29, 2017
  8. TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller
  9. Cancer Space Update: Mixed Week for Pfizer, Roche Falters
  10. Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
  11. TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
  12. Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro’s Ovarian Cancer Drug
  13. TESARO Receives Positive CHMP Opinion for ZEJULA®
  14. ETFs with exposure to TESARO, Inc. : September 12, 2017
  15. TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting

SEC Filings

  1. CT ORDER - Confidential treatment order 171100952
  2. 8-K - Current report 171090492
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171078694
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171020147
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015494
  6. 8-K - Current report 171014672
  7. 8-K - Current report 17984438
  8. 8-K - Current report 17904501
  9. 8-K - Current report 17889968
  10. CT ORDER - Confidential treatment order 17884047